{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:02:04Z","timestamp":1789884124195,"version":"4.0.1"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T00:00:00Z","timestamp":1320019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Moderate\/severe psoriasis combined with psoriatic arthritis (PsA) impairs health\u2010related quality of life (QoL). Etanercept, a fully human tumour necrosis factor\u2010\u03b1 receptor fusion protein, is approved for treatment of both diseases.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To compare patient\u2010reported health outcomes (PROs) of two etanercept regimens in patients with moderate\/severe psoriasis and PsA.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In this randomized, double\u2010blind, multicenter study, participants received etanercept 50\u2003mg twice weekly (BIW; <jats:italic>n<\/jats:italic>\u2003=\u2003379) or 50\u2003mg weekly (QW; <jats:italic>n<\/jats:italic>\u2003=\u2003373) for 12\u2003weeks and open\u2010label etanercept 50\u2003mg QW for 12 additional weeks. PROs included: the EuroQOL\u20105D (EQ\u20105D), which measures general health status and consists of the utility index measuring five dimensions of health, and a visual analogue scale (VAS) allowing patients to assess health status; the Dermatology Life Quality Index (DLQI), which measures the impact of skin disease on QoL; the Health Assessment Questionnaire\u2010Disability Index (HAQ\u2010DI), an assessment of physical function; the Hospital Anxiety and Depression Scale (HADS), which screens for anxiety and depression symptoms; and individual questions on general health, disease activity, fatigue, itching, joint pain and morning stiffness.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> At baseline, patients reported QoL worse than that seen in many chronic medical conditions. Significant within\u2010group improvements in each PRO occurred from baseline to Week 12 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) in both groups and were maintained at Week 24; DLQI, EQ\u20105D, HAQ\u2010DI and self assessments improved significantly (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) from baseline as early as Week 3. At Week 12, but not Week 24, improvement in DLQI, itching and psoriasis activity was greater in the BIW arm (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030.004). Improvements in other PROs were always similar between groups.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Greater improvements in PROs specific to skin disorders were seen with etanercept BIW than QW at Week 12, but not at Week 24. Both etanercept regimens led to sustained PRO improvements, starting as early as Week 3.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04308.x","type":"journal-article","created":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T06:03:06Z","timestamp":1320040986000},"page":"1436-1443","source":"Crossref","is-referenced-by-count":55,"title":["Self\u2010reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens"],"prefix":"10.1111","volume":"26","author":[{"given":"R.","family":"Gniadecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Molta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Freundlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Zbrozek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04038.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.11.005"},{"key":"e_1_2_6_4_2","first-page":"883","article-title":"Risks and benefits of tumor necrosis factor\u2010alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials","volume":"35","author":"Saad AA","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-006-0064-9"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701364768"},{"key":"e_1_2_6_7_2","first-page":"511","article-title":"Validating the SF\u201036 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted JA","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient\u2010membership survey","volume":"137","author":"Krueger G","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_9_2","first-page":"127","article-title":"Psoriatic arthritis (PSA) \u2013 an analysis of 220 patients","volume":"62","author":"Gladman DD","year":"1987","journal-title":"Q J Med"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00032.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06343.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c147"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(01)00296-3"},{"key":"e_1_2_6_17_2","first-page":"167","article-title":"The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce B","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-71"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199405050-00005"},{"key":"e_1_2_6_20_2","volume-title":"Population Norms for EQ\u20105D","author":"Kind P","year":"1999"},{"key":"e_1_2_6_21_2","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials? (OMERACT) group guidelines [abstract]","volume":"63","author":"Mease PJ","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237871"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200422001-00004"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"key":"e_1_2_6_25_2","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll KB","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155500300012873"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948130"},{"key":"e_1_2_6_28_2","first-page":"1374","article-title":"Improvements in patient\u2010reported outcomes in moderate\u2010to\u2010severe psoriasis patients receiving continuous or paused etanercept treatment over 54\u2003weeks: the CRYSTEL study","volume":"23","author":"Daud\u00e9n E","year":"2009","journal-title":"JEADV"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.05.004"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291796004382"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068585"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_6_35_2","volume-title":"SF\u201036 Physical and Mental Health Summary Scales: a Manual for Users of Version 1","author":"Ware JE","year":"2001"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057901"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040196"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04308.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04308.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T22:30:08Z","timestamp":1697322608000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04308.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,31]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04308.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04308.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,31]]}}}